Portal de Periódicos da CAPES

Special Section on Implications of CATIE: What CATIE Found: Results From the Schizophrenia Trial

2008; American Psychiatric Association; Volume: 59; Issue: 5 Linguagem: Inglês

10.1176/ps.2008.59.5.500

1557-9700

Marvin S. Swartz, T. Scott Stroup, Joseph P. McEvoy, Sonia M. Davis, Robert A. Rosenheck, Richard S.E. Keefe, John Hsiao, Jeffrey A. Lieberman,

Neurotransmitter Receptor Influence on Behavior

A lthough studies of secondgeneration antipsychotics in schizophrenia have indicated that these drugs are comparable to the first-generation antipsychotics in reducing psychotic symptoms and that they produce few neurologic effects, with the exception of clozapine, the evidence for their superior efficacy and safety has been inconsistent (1-10).As a result of dominant prescribing preferences for second-generation antipsychotics over first-generation antipsychotics, despite their greater cost, questions have been raised about the clinical advantages and the cost-effectiveness of the second-generation antipsychotics.This article provides an overview of the primary outcomes of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), which was supported by the National Institute of Mental Health and designed to compare the effectiveness of first-and second-generation antipsychotic medications (11)(12)(13)(14).In this overview we review the design, methods, and results of CATIE, with a focus on the implications and limitations of the trial. CATIE design and procedures Design and measuresThe rationale, design, and methods of CATIE have been previously described (11-14).The study was conducted between October 2001 and December 2004 at 57 U.S. clinical sites.